ADMA Biologics
ADMA
ADMA
52 hedge funds and large institutions have $58M invested in ADMA Biologics in 2018 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 17 increasing their positions, 18 reducing their positions, and 12 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
less repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
less ownership
Funds ownership: →
less funds holding
Funds holding: →
42% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 12
65% less capital invested
Capital invested by funds: $165M → $58M (-$107M)
67% less funds holding in top 10
Funds holding in top 10: 3 → 1 (-2)
Holders
52
Holding in Top 10
1
Calls
$2K
Puts
$2K
Top Buyers
| 1 | +$822K | |
| 2 | +$317K | |
| 3 | +$151K | |
| 4 |
DG
Delek Group
Herzliya,
Israel
|
+$147K |
| 5 |
CCM
Consonance Capital Management
New York
|
+$117K |
Top Sellers
| 1 | -$1.28M | |
| 2 | -$1.17M | |
| 3 | -$664K | |
| 4 |
BC
Broadfin Capital
New York
|
-$568K |
| 5 |
JP Morgan Chase
New York
|
-$479K |